| Field | Specification |
|---|---|
| Mfr No | |
| Species |
786-O cells are a human renal cell carcinoma cell line derived from a primary clear cell adenocarcinoma of the kidney. This cell line is frequently used in the study of renal cell carcinoma (RCC), providing valuable insights into the biological characteristics and treatment responses of this cancer type.
The 786-O cell line exhibits a clear cell morphology, typical of the most common form of kidney cancer, and is characterized by specific genetic alterations, including the loss of the von Hippel-Lindau (VHL) tumor suppressor gene. This genetic feature is significant as it plays a crucial role in the pathogenesis of many clear cell renal carcinomas by influencing hypoxia-inducible pathways, which are central to cellular responses to low oxygen conditions.
These cells are particularly useful for studying the molecular mechanisms involved in tumor growth and survival, including pathways related to angiogenesis, metabolism, and cell cycle regulation. Due to their VHL deficiency, 786-O cells are an excellent model for researching the effects of hypoxia and for testing drugs that target hypoxia-related pathways.
In addition to their application in basic cancer research, 786-O cells are also used in preclinical studies to evaluate the efficacy of new therapeutic agents, especially those targeting the angiogenic processes driven by the overexpression of hypoxia-inducible factors (HIFs). This includes therapies that inhibit the HIF pathway, tyrosine kinase inhibitors, and immune checkpoint inhibitors.
Overall, 786-O cells provide a robust model for advancing our understanding of the molecular underpinnings of renal cell carcinoma and for developing targeted therapies that could improve treatment outcomes for patients with this challenging disease.
—
- Antigen expression: CAIx +, as confirmed by FACS analysis.
- Tumorigenic: In immunosuppressed hamsters
- Products: The cells produce a PTH (parathyroid hormone) like peptide that is identical to peptides produced by breast and lung tumors. It has an N terminal sequence similar to PTH, has PTH like activity, and has a molecular weight of 6000 daltons.
- Karyotype: Hypertriploid. Y was present in 60% of cells examined
- cultureMedium: RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a)
- supplements: Supplement the medium with 10% FBS
- dissociationReagent: Accutase
- doublingTime: 24 hours
- subculturing: Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium.
- seedingDensity: 1 x 104 cells/cm2 will result in a confluent monolayer within 4 days.
- fluidRenewal: 2 to 3 times per week
- postThawRecovery: After thawing, plate the cells at 4 x 104 cells/cm2 and allow the cells to recover from the freezing process and to adhere for at least 48 hours.
- freezeMedium: As a cryopreservation medium, use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress.
10%
OFF
15%OFF
20%
OFF
$50
OFF
FREE
SAMPLE
